Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) Return on Capital Employed: 2011-2025

Historic Return on Capital Employed for Myriad Genetics (MYGN) over the last 15 years, with Sep 2025 value amounting to -0.76%.

  • Myriad Genetics' Return on Capital Employed fell 63.00% to -0.76% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.76%, marking a year-over-year decrease of 63.00%. This contributed to the annual value of -0.13% for FY2024, which is 12.00% up from last year.
  • Latest data reveals that Myriad Genetics reported Return on Capital Employed of -0.76% as of Q3 2025, which was down 16.62% from -0.65% recorded in Q2 2025.
  • Over the past 5 years, Myriad Genetics' Return on Capital Employed peaked at -0.12% during Q3 2022, and registered a low of -0.76% during Q3 2025.
  • Over the past 3 years, Myriad Genetics' median Return on Capital Employed value was -0.24% (recorded in 2024), while the average stood at -0.29%.
  • Per our database at Business Quant, Myriad Genetics' Return on Capital Employed climbed by 17bps in 2024 and then tumbled by 63bps in 2025.
  • Quarterly analysis of 5 years shows Myriad Genetics' Return on Capital Employed stood at -0.17% in 2021, then grew by 4bps to -0.13% in 2022, then decreased by 13bps to -0.26% in 2023, then climbed by 12bps to -0.14% in 2024, then plummeted by 63bps to -0.76% in 2025.
  • Its Return on Capital Employed was -0.76% in Q3 2025, compared to -0.65% in Q2 2025 and -0.14% in Q1 2025.